Project Grant HT9425261E468
Award Date 9/1/26
Completion Date 8/31/30
Dollars Obligated $4.2M
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Boston, MA 02215, USA
Similar Awards
- The Defense Health Agency awarded Dana-Farber Cancer Institute, Inc. $4.199 million on September 1, 2026, under the Military Medical Research and Development program (CFDA 12.420) to conduct a Phase 1/2 study of HALK.CAR T cells for patients with relapsed/refractory high-risk neuroblastoma. The study runs through August 31, 2030, with work performed in Boston, Massachusetts. The award funds clinical and translational research on chimeric antigen receptor T-cell therapy targeting pediatric...
- The Defense Health Agency awarded Dana-Farber Cancer Institute, Inc. $1.12 million under the Military Medical Research and Development program (CFDA 12.420) on September 1, 2026, to support resource development to improve outcomes for blastic plasmacytoid dendritic cell neoplasm. The award funds basic and translational research over a four-year performance period ending August 31, 2030, with work performed in Boston, Massachusetts. The program supports innovative biomedical research to transform...
- The Defense Health Agency has awarded a $1,483,340 Project Grant under the Military Medical Research and Development program (CFDA 12.420) to the Dana-Farber Cancer Institute, Inc. (doing business as DFCI) in Boston, MA. The grant, with a performance period from June 1, 2024 to May 31, 2028, will fund research to harness extracellular domain (ECD) cleavage of anaplastic lymphoma kinase (ALK) for immunotherapy against neuroblastoma. As a non-profit hospital and cancer research center, DFCI will...
- The Defense Health Agency awarded Dana-Farber Cancer Institute, Inc. $723,699 on July 15, 2026, under the Military Medical Research and Development program (CFDA 12.420) for a project titled "Optimizing Immunotherapy for Pediatric Solid Tumors." The award covers research and development activities performed in Boston, Massachusetts, with a period of performance through July 14, 2029. The program supports basic, applied, and advanced biomedical research to transform health care for...
- The Defense Health Agency awarded Dana-Farber Cancer Institute, Inc., $1,014,596 on July 15, 2026, under the Military Medical Research and Development program (CFDA 12.420) to support research optimizing immunotherapy for pediatric solid tumors. Performance runs through July 14, 2029, at the institute's Boston, Massachusetts location. The grant advances the Defense Health Agency's mission to transform health care for Service Members and the American public through innovative biomedical research,...
- The U.S. Defense Health Agency has awarded a $712,000 Project Grant through the Military Medical Research and Development program (CFDA 12.420) to the Dana-Farber Cancer Institute, Inc. (doing business as Dfci) in Boston, MA. The 2-year grant, with a period of performance from July 1, 2024 to June 30, 2026, will support a longitudinal study to identify mechanisms of treatment resistance in rhabdomyosarcoma through circulating tumor DNA analysis. As a not-for-profit hospital and cancer research...
- The Defense Health Agency awarded Dana-Farber Cancer Institute, Inc., $4.199 million on September 1, 2026, under the Military Medical Research and Development program (CFDA 12.420) to develop optimized B7-H3 CAR T cells for children and young adults with sarcomas and other B7-H3–positive solid tumors. The award funds research and development of engineered T cell immunotherapy targeting pediatric and young adult solid tumors expressing the B7-H3 antigen. Work is performed in Boston,...
- The Department of Defense's Military Medical Research and Development program (CFDA 12.420) has awarded a $889,995.00 Project Grant to the Dana-Farber Cancer Institute, Inc. (dba Dfci), a non-profit hospital and cancer research center in Boston, MA. The grant, effective June 1, 2024 through May 31, 2027, supports research to "dissect the interplay of molecular and spatial architectures with clinical states in prostate cancer." This federal funding will enable Dana-Farber to conduct...
- <p>The Defense Health Agency awarded Dana-Farber Cancer Institute, Inc. $559,999 on September 1, 2026, under the Military Medical Research and Development program (CFDA 12.420) to develop novel digenic combination therapies for treatment of pancreatic cancer. The award runs through August 31, 2028, with work performed in Boston, Massachusetts. The assistance type is a project grant.</p>
- The Defense Health Agency has awarded a $4,954,747 Project Grant to the Dana-Farber Cancer Institute, Inc. (doing business as Dfci) to conduct research under the Military Medical Research and Development program (CFDA 12.420). The grant, titled "Novel Immunologic Discovery Platforms to Prevent Metastasis and Recurrence in Breast Cancer," will fund a four-year research project focused on developing new immunology-based approaches to prevent the spread and return of breast cancer. As a...